The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
ELEVATED LEVELS OF CIRCULATING INTERLEUKIN-6 AND TRANSFORMING GROWTH FACTOR-beta 1 IN PATIENTS WITH METASTATIC PROSTATIC CARCINOMA
Abstract
PURPOSE: Specific cytokines have been found to be secreted by and influence the growth of prostate cancers in cell culture. Interleukin-6 (IL-6), tumor necrosis factor alpha (TNFalpha), granulocyte macrophage-colony stimulating factor (GM-CSF) and transforming growth factor-beta1 (TGF-beta1) have all been closely associated with prostate cancer. We analyzed the levels of these cytokines in the systemic circulation of patients with varying stages of prostate cancer compared to controls. MATERIALS AND METHODS: Serum IL-6, TNFalpha and GM-CSF were measured using commercially available enzyme linked immunosorbent assays in 5 groups of patients, including controls-19 men presenting to prostate cancer screening with normal digital rectal examination and serum prostate specific antigen (PSA) no greater than 2.0 ng./ml., stage pT2-19 with cancer confined to the prostate in the radical prostatectomy specimen, stage pT3-10 with extraprostatic extension and/or seminal vesicle involvement, stage N1-12 with lymph node metastases at pelvic lymph node dissection, and stage M1-9 with bone metastases. Platelet poor plasma TGF-beta1 was measured using a commercially available enzyme linked immunosorbent assay in controls and patients with stage M1 disease only because it was not available for patients with stages pT2, pT3 and N1 disease. No patient had a history of any other malignancy. All blood specimens were collected before surgery and/or androgen ablation. Statistical analysis was done with the Kruskal-Wallis analysis of variance. RESULTS: Serum IL-6 and platelet poor plasma TGF-beta1 were significantly elevated in patients with clinically evident metastases (p = 0.0008 and 0.0412, respectively) while serum GM-CSF and TNFalpha were not. IL-6 and TGF-beta1 correlated with increasing serum PSA (p = 0.0335 and 0.0386, respectively). GM-CSF did not correlate with PSA or age. In multivariate analysis TNFalpha correlated with age but not PSA. CONCLUSIONS: IL-6 and TGF-beta1 correlate with tumor burden as assessed by serum PSA or clinically evident metastases. Further research is needed to determine the response to androgen ablation as well as the source(s) and actions of these cytokines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Balkwill, F. R., & Burke, F. (1989) · Immunology Today · doi:10.1016/0167-5699(89)90085-6 · Cited by 783
Miyazono, K., Hellman, U., Wernstedt, C., & Heldin, C. H. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68800-3 · Cited by 637
FACTORS AFFECTING THE RESPONSE OF IMMUNISED GUINEAPIGS TO ANTIGENIC STIMULUS
Hartley, P., & Hartley, O. (1949) · The Lancet · doi:10.1016/s0140-6736(49)92093-0 · Cited by 470
Yang, E. Y., & Moses, H. L. (1990) · The Journal of cell biology · doi:10.1083/jcb.111.2.731 · Cited by 464
EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCER
Balkwill, F., Burke, F., Talbot, D., Tavernier, J., Osborne, R., Naylor, S., Durbin, H., & Fiers, W. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91850-2 · Cited by 418
Dual role of tumor necrosis factor-alpha in angiogenesis.
Fajardo, L. F., Kwan, H. H., Kowalski, J., Prionas, S. D., & ALLISON, A. C. (1992) · PubMed · Cited by 355
Interleukins and the immune system 1.
O’Garra, A. (1989) · PubMed · Cited by 309
Okamoto, M., Lee, C., & Oyasu, R. (1997) · PubMed · Cited by 304
Interleukin-6: A candidate mediator of human prostate cancer morbidity
Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W.-S., Kim, W. Y., & Simons, J. W. (1995) · Urology · doi:10.1016/s0090-4295(99)80034-x · Cited by 286
Tsushima, H., Kawata, S., Tamura, S., Ito, N., Shirai, Y., Kiso, S., Imai, Y., Shimomukai, H., Nomura, Y., Matsuda, Y., et al. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8566583 · Cited by 284
Pleiotropy and redundancy: T cell-derived lymphokines in the immune response
Paul, W. E. (1989) · Cell · doi:10.1016/0092-8674(89)90121-9 · Cited by 231
Kong, F.-M., Anscher, M. S., Murase, T., Abbott, B. D., Iglehart, J. D., & Jirtle, R. L. (1995) · Annals of Surgery · doi:10.1097/00000658-199508000-00007 · Cited by 201
Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer
Ivanovic, V., Melman, A., Davis-Joseph, B., Valcic, M., & Geliebter, J. (1995) · Nature Medicine · doi:10.1038/nm0495-282 · Cited by 176
Association of transforming growth factor-β1 with prostate cancer: An immunohistochemical study
Truong, L. D., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T., & Thompson, T. C. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90055-l · Cited by 167
Self-citationMoradi, M. M., Carson, L. F., Twiggs, L. B., Weinberg, J. B., Haney, A. F., & Ramakrishnan, S. (1993) · Cancer · doi:10.1002/1097-0142(19931015)72:8<2433::aid-cncr2820720822>3.0.co;2-l · Cited by 156
Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.
Siegall, C. B., Schwab, G., Nordan, R. P., FitzGerald, D. J., & Pastan, I. (1990) · PubMed · Cited by 153
INTERLEUKINS AND THE IMMUNE SYSTEM 2
O’Garra, A. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92640-8 · Cited by 139
Eastham, J. A., Truong, L. D., Rogers, E., Kattan, M. W., Flanders, K. C., Scardino, P. T., & Thompson, T. C. (1995) · PubMed · Cited by 106
Self-citationTransforming growth factor β1 as a biomarker for prostate cancer
Thompson, T. C., Truong, L. D., Timme, T. L., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T., & Park, S. H. (1992) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240501212 · Cited by 70
Self-citationElevated Levels of Circulating Transforming Growth Factor-β 1 in Patients with the Sepsis Syndrome
Marie, C., Cavaillon, J., & Losser, M.-R. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-6-199609150-00034 · Cited by 66
Elevated Levels of Plasma Transforming Growth Factor‐β in Patients with Hepatocellular Carcinoma
Shirai, Y., Kawata, S., Ito, N., Tamura, S., Takaishi, K., Kiso, S., Tsushima, H., & Matsuzawa, Y. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb01964.x · Cited by 63
Hoosein, N. M., Abdul, M., McCabe, R., Gerö, E., Deftos, L. J., Banks, M., Hodges, S., Finn, L. D., & Logothetis, C. J. (1995) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/1078-1439(96)00012-9 · Cited by 47
Induction of transforming growth factor beta in hormonally treated human prostate cancer
Muir, G., Butta, A., SHEARER, R. J., Fisher, C., Dearnaley, D. P., Flanders, K. C., Sporn, M. B., & Colletta, A. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.21 · Cited by 35
Elevation of serum transforming growth factor-β1 Level in patients with metastatic prostate cancer
Kakehi, Y., Oka, H., Mitsumori, K., Itoh, N., Ogawa, O., & Yoshida, O. (1996) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/s1078-1439(96)00078-6 · Cited by 18
Cited by
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
IL-6/IL-6 receptor system and its role in physiological and pathological conditions
Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M., & Shiina, M. (2012) · Clinical Science · doi:10.1042/cs20110340 · Cited by 895
TGF- β signaling in cancer – a double-edged sword
Akhurst, R. J., & Derynck, R. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02130-4 · Cited by 756
Role of transforming growth factor-β superfamily signaling pathways in human disease
Gordon, K. J., & Blobe, G. C. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.01.006 · Cited by 641
Active Nanodiamond Hydrogels for Chemotherapeutic Delivery
Huang, H., Pierstorff, E., Osawa, E., & Ho, D. (2007) · Nano Letters · doi:10.1021/nl071521o · Cited by 556
Metadata
- Authors
- ADLER, H. L., McCURDY, M. A., KATTAN, M. W., TIMME, T. L., SCARDINO, P. T., & THOMPSON, T. C.
- Venue
- Journal of Urology
- Published
- 1999-01
- Volume
- 161
- Issue
- 1
- Pages
- 182-187
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2073069369
- Cited by
- 386
- References
- 25
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.